Clinical trial / 1993
Grapefruit juice and naringenin inhibit CYP1A2-dependent caffeine metabolism in humans.
Researchers evaluated the effects of grapefruit juice and naringenin on human CYP1A2 activity using caffeine as a probe substrate. In vitro, naringin competitively inhibited caffeine 3-demethylation by human liver microsomes (Ki = 7-29 microM). In vivo among 12 participants, grapefruit juice (1.2 l day-1 containing 0.5 g l-1 naringin) decreased oral caffeine clearance by 23% (95% CI: 7%-30%) and prolonged its half-life by 31% (95% CI: 20%-44%). The authors concluded that while grapefruit juice inhibits CYP1A2, the small in vivo effect suggests it generally should not cause clinically significant inhibition of other CYP1A2 drug substrates.
- Study type
- Intervention trial with in vitro microsomal component
- Who was studied
- 12 human participants (in vivo) and human liver microsomes (in vitro)
- What was measured
- Caffeine oral clearance, half-life, and in vitro caffeine 3-demethylation inhibition
THE PAPER
Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man.
Fuhr U, Klittich K, Staib AH. Br J Clin Pharmacol, 1993.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.